BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 27269808)

  • 1. An Effective Virtual Screening Protocol To Identify Promising p53-MDM2 Inhibitors.
    Tortorella P; Laghezza A; Durante M; Gomez-Monterrey I; Bertamino A; Campiglia P; Loiodice F; Daniele S; Martini C; Agamennone M
    J Chem Inf Model; 2016 Jun; 56(6):1216-27. PubMed ID: 27269808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
    Sirous H; Chemi G; Campiani G; Brogi S
    Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors.
    Xue X; Bao G; Zhang HQ; Zhao NY; Sun Y; Zhang Y; Wang XL
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30513790
    [No Abstract]   [Full Text] [Related]  

  • 4. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach.
    Leão M; Pereira C; Bisio A; Ciribilli Y; Paiva AM; Machado N; Palmeira A; Fernandes MX; Sousa E; Pinto M; Inga A; Saraiva L
    Biochem Pharmacol; 2013 May; 85(9):1234-45. PubMed ID: 23428467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.
    Atatreh N; Ghattas MA; Bardaweel SK; Rawashdeh SA; Sorkhy MA
    Drug Des Devel Ther; 2018; 12():3741-3752. PubMed ID: 30464405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-MDM2 interaction inhibitors.
    Xue X; Wei JL; Xu LL; Xi MY; Xu XL; Liu F; Guo XK; Wang L; Zhang XJ; Zhang MY; Lu MC; Sun HP; You QD
    J Chem Inf Model; 2013 Oct; 53(10):2715-29. PubMed ID: 24050442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
    Ding K; Lu Y; Nikolovska-Coleska Z; Wang G; Qiu S; Shangary S; Gao W; Qin D; Stuckey J; Krajewski K; Roller PP; Wang S
    J Med Chem; 2006 Jun; 49(12):3432-5. PubMed ID: 16759082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
    Riaz M; Ashfaq UA; Qasim M; Yasmeen E; Ul Qamar MT; Anwar F
    Anticancer Drugs; 2017 Oct; 28(9):1032-1038. PubMed ID: 28723868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
    Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
    Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.
    Lu Y; Nikolovska-Coleska Z; Fang X; Gao W; Shangary S; Qiu S; Qin D; Wang S
    J Med Chem; 2006 Jun; 49(13):3759-62. PubMed ID: 16789731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.
    Wang W; Lv D; Qiu N; Zhang L; Hu C; Hu Y
    Bioorg Med Chem; 2013 Jun; 21(11):2886-94. PubMed ID: 23611770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective virtual screening for novel p53-MDM2 inhibitors using ultrafast shape recognition.
    Patil SP; Ballester PJ; Kerezsi CR
    J Comput Aided Mol Des; 2014 Feb; 28(2):89-97. PubMed ID: 24554192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.
    Wang W; Shangguan S; Qiu N; Hu C; Zhang L; Hu Y
    Bioorg Med Chem; 2013 Jun; 21(11):2879-85. PubMed ID: 23601819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
    Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.
    Gessier F; Kallen J; Jacoby E; Chène P; Stachyra-Valat T; Ruetz S; Jeay S; Holzer P; Masuya K; Furet P
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3621-5. PubMed ID: 26141769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated virtual screening and molecular dynamics simulation revealed promising drug candidates of p53-MDM2 interaction.
    Oyedele AK; Adelusi TI; Ogunlana AT; Adeyemi RO; Atanda OE; Babalola MO; Ashiru MA; Ayoola IJ; Boyenle ID
    J Mol Model; 2022 May; 28(6):142. PubMed ID: 35536362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
    Zheng GH; Shen JJ; Zhan YC; Yi H; Xue ST; Wang Z; Ji XY; Li ZR
    Eur J Med Chem; 2014 Jun; 81():277-88. PubMed ID: 24852275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
    Neochoritis CG; Atmaj J; Twarda-Clapa A; Surmiak E; Skalniak L; Köhler LM; Muszak D; Kurpiewska K; Kalinowska-Tłuścik J; Beck B; Holak TA; Dömling A
    Eur J Med Chem; 2019 Nov; 182():111588. PubMed ID: 31421630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand-Based and Docking-Based Virtual Screening of MDM2 Inhibitors as Potent Anticancer Agents.
    Li BH; Ge JQ; Wang YL; Wang LJ; Zhang Q; Bian C
    Comput Math Methods Med; 2021; 2021():3195957. PubMed ID: 34413896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.